Vertex Pharmaceuticals Inc. (VRTX)
NASDAQ:VRTX
Want to see VRTX full AI Analyst Report?
Top Page
Vertex Pharmaceuticals
(NASDAQ:VRTX)
Select Model
Select Model
Rating:77Outperform
Price Target:
$509.00
▲(15.37% Upside)
Action:Reiterated
Date:05/14/26
VRTX scores well primarily due to strong financial performance (high margins, low leverage, and solid cash generation) and a constructive earnings outlook with reiterated guidance and meaningful pipeline/regulatory progress. The score is tempered by mixed/weakening technical momentum (negative MACD) and only moderate valuation support given the ~27.5 P/E and no dividend yield.
Positive Factors
High gross margins and profitability
Sustained mid-80% gross margins and strong operating/net margins indicate durable pricing power and efficient product economics for Vertex’s therapies. High margins support long-term R&D funding, commercial expansion and shareholder returns, providing structural earnings resilience beyond quarter-to-quarter swings.
Negative Factors
Concentration in cystic fibrosis franchise
A continued heavy reliance on CFTR modulators leaves Vertex exposed to payer pricing pressure, label-eligibility ceilings and any CF-specific competitive or patent risks. Structural revenue concentration raises stakes on successful geographic expansion and on-time lifecycle management for CF products.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margins and profitability
Sustained mid-80% gross margins and strong operating/net margins indicate durable pricing power and efficient product economics for Vertex’s therapies. High margins support long-term R&D funding, commercial expansion and shareholder returns, providing structural earnings resilience beyond quarter-to-quarter swings.
Read all positive factors
Vertex Pharmaceuticals Key Performance Indicators (KPIs)
Any
Revenue by Geography
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Data provided by:
The Fly
The FlyVertex Pharmaceuticals (VRTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$110.03B
Dividend YieldN/A
Average Volume (3M)1.17M
Price to Earnings (P/E)27.5
Beta (1Y)0.53
Revenue Growth11.75%
EPS GrowthN/A
CountryUS
Employees6,100
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)17.01
Shares Outstanding253,805,420
10 Day Avg. Volume1,303,823
30 Day Avg. Volume1,171,086
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)6.21
Price to Sales (P/S)9.60
P/FCF Ratio36.30
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue8.71
Enterprise Value/Gross Profit10.10
Enterprise Value/Ebitda20.59
Forecast
1Y Price Target
$562.90Price Target Upside27.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering24
EPS Forecast (FY)19.32
Revenue Forecast (FY)$13.04B
Vertex Pharmaceuticals Business Overview & Revenue Model
Company Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who h...
How the Company Makes Money
Vertex primarily makes money by selling prescription medicines, with the large majority of revenue historically generated from its cystic fibrosis franchise. Key CF products include TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor), SYMDEKO/SYMK...
Vertex Pharmaceuticals Earnings Call Summary
Earnings Call Date:May 04, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Jul 30, 2026
Earnings Call Sentiment Positive
Overall the call conveyed a positive, execution-focused tone: strong top-line results (8% revenue growth to $2.99B), major commercial milestones (AlifTrack >$1B cumulative revenue, >1M Gernavix prescriptions, >500 KASJEVY patients initiated), and a standout Phase III interim win for povitacicept in IgAN with rapid BLA submission. At the same time, the company disclosed a program discontinuation (VX-522) due to tolerability, increased SG&A (30% YoY) tied to commercialization investments, and several important longer-term readouts (eGFR for renal programs, enaxaplin and AMPLITUDE results) remain pending. The positives — strong revenue and multiple high-impact pipeline/regulatory achievements — outweigh the challenges and near-term variability risks.Positive Updates
Strong Q1 Revenue Growth
Total product revenue of $2.99 billion in Q1 2026, up 8% year-over-year; non-GAAP operating income of $1.31 billion (vs. $1.18 billion prior year); non-GAAP net income of $1.1 billion and EPS of $4.47 (up from $4.06).
Negative Updates
Discontinuation of VX-522 mRNA Program
Vertex discontinued the VX-522 mRNA program for people who produce no CFTR protein due to unresolved tolerability issues (lung inflammation likely related to LNP delivery). Early termination prevents assessment of efficacy and full safety; company will close out the study.
Read all updates
Q1-2026 Updates
Positive
Negative
Strong Q1 Revenue Growth
Total product revenue of $2.99 billion in Q1 2026, up 8% year-over-year; non-GAAP operating income of $1.31 billion (vs. $1.18 billion prior year); non-GAAP net income of $1.1 billion and EPS of $4.47 (up from $4.06).
Read all positive updates
Company Guidance
Vertex reiterated 2026 guidance for total revenue of $12.95–$13.10 billion (growth of 8–9%), including an expectation of $500 million-plus from non‑CF products, with full‑year gross margin forecast just under 86%. Management reiterated combined non‑GAAP operating expenses of $5.65–$5.75 billion and a non‑GAAP effective tax rate of 19.5%–20.5% (Q1 non‑GAAP ETR was 19.6%), and said guidance reflects expected foreign‑exchange impacts net of hedging. They expect Gernavix prescriptions to more than triple in 2026 (base ~550k in 2025) with gross‑to‑net normalizing in H2, and highlighted strong visibility to the $500M+ non‑CF goal driven by growing KASJEVY and GERNAVICS contributions (Q1 KASJEVY $43M; GERNAVICS $29M). The company ended Q1 with $13.0 billion in cash and investments and deployed ~$344 million to repurchase ~741k shares, while reiterating a capital focus on innovation and commercial investment.Vertex Pharmaceuticals Financial Statement Overview
Summary
Income Statement
86
Very Positive
Balance Sheet
88
Very Positive
Cash Flow
83
Very Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.26B | 12.07B | 11.02B | 9.87B | 8.93B | 7.57B |
| Gross Profit | 10.57B | 10.27B | 9.49B | 8.61B | 7.85B | 6.67B |
| EBITDA | 5.19B | 4.97B | 486.30M | 4.61B | 4.44B | 2.92B |
| Net Income | 4.34B | 3.95B | -535.60M | 3.62B | 3.32B | 2.34B |
Balance Sheet | ||||||
| Total Assets | 26.48B | 26.14B | 22.53B | 22.73B | 18.15B | 13.43B |
| Cash, Cash Equivalents and Short-Term Investments | 7.25B | 6.61B | 6.12B | 11.22B | 10.78B | 7.52B |
| Total Debt | 1.99B | 3.88B | 1.75B | 808.40M | 899.70M | 967.40M |
| Total Liabilities | 7.12B | 7.48B | 6.12B | 5.15B | 4.24B | 3.33B |
| Stockholders Equity | 19.36B | 18.67B | 16.41B | 17.58B | 13.91B | 10.10B |
Cash Flow | ||||||
| Free Cash Flow | 3.71B | 3.19B | -790.30M | 3.28B | 3.93B | 2.41B |
| Operating Cash Flow | 4.24B | 3.63B | -492.60M | 3.54B | 4.13B | 2.64B |
| Investing Cash Flow | -1.32B | -945.40M | -3.77B | -3.14B | -321.10M | -340.90M |
| Financing Cash Flow | -2.12B | -2.26B | -1.49B | -562.20M | -67.70M | -1.48B |
Vertex Pharmaceuticals Technical Analysis
Negative
441.20
Price Trends
440.29
Negative
454.72
Negative
434.75
Negative
Market Momentum
-1.09
Negative
48.09
Neutral
26.18
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VRTX, the sentiment is Negative. The current price of 441.2 is above the 20-day moving average (MA) of 433.03, above the 50-day MA of 440.29, and above the 200-day MA of 434.75, indicating a neutral trend. The MACD of -1.09 indicates Negative momentum. The RSI at 48.09 is Neutral, neither overbought nor oversold. The STOCH value of 26.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VRTX.
Vertex Pharmaceuticals Risk Analysis
Vertex Pharmaceuticals disclosed 50 risk factors in its most recent earnings report. Vertex Pharmaceuticals reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Vertex Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | $19.46B | 15.46 | 29.31% | ― | 21.48% | 1853.63% | |
77 Outperform | $110.03B | 27.50 | 23.93% | ― | 11.75% | ― | |
75 Outperform | $67.37B | 27.62 | 14.32% | 0.45% | 5.92% | 1.85% | |
75 Outperform | $50.73B | 39.90 | 16.82% | ― | 90.23% | 51.88% | |
63 Neutral | $40.12B | 53.36 | 98.29% | ― | 82.57% | ― | |
55 Neutral | $22.99B | -8.99 | -6.67% | ― | 10.01% | -71.78% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
VRTX
Vertex Pharmaceuticals
434.52
-11.48
-2.57%
ALNY
Alnylam Pharma
297.45
7.49
2.58%
INCY
Incyte
97.16
32.91
51.23%
REGN
Regeneron
638.88
53.75
9.19%
ARGX
Argenx Se
806.46
218.85
37.24%
BNTX
BioNTech SE
92.14
-6.41
-6.50%
Vertex Pharmaceuticals Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Vertex Shareholders Endorse Board, Governance and Equity Plan
Positive
May 13, 2026
At its annual meeting held on May 13, 2026, Vertex Pharmaceuticals’ shareholders elected ten directors, including CEO Reshma Kewalramani and Executive Chairman Jeffrey Leiden, to serve on the board until the 2027 annual meeting, reinforcing ...
Executive/Board ChangesShareholder Meetings
Vertex Director Upadhyay to Step Down Amid CFO Move
Neutral
Apr 29, 2026
On April 28, 2026, Vertex Pharmaceuticals said director Suketu Upadhyay informed its board that he would not stand for re‑election at the company’s 2026 annual meeting, as he has been named the forthcoming chief financial officer of In...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Vertex Advances FDA Filing for IgA Nephropathy Therapy
Positive
Mar 31, 2026
Vertex Pharmaceuticals has completed the rolling submission of a Biologics License Application to the U.S. Food and Drug Administration for povetacicept, seeking accelerated approval to treat immunoglobulin A nephropathy in adults. By using a prio...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.